AbbVie Shares Surge 2.39% with $21.62 Billion Trading Volume Ranking 30th in Market Activity

AbbVie (ABBV) shares rose 2.39% on May 15, 2025, with a trading volume of $21.62 billion, ranking 30th in the day's market activity.

AbbVie has announced a significant collaboration with ADARx Pharmaceuticals to develop next-generation siRNA therapies. This partnership focuses on multiple therapeutic areas, including neuroscience, immunology, and oncology. The collaboration leverages ADARx's proprietary RNA technology and discovery expertise, combined with AbbVie's strengths in antibody engineering and drug delivery. This strategic move aims to enhance the development of precise and sustained mRNA silencing therapies, potentially revolutionizing treatment approaches in these critical areas.

In addition to this collaboration, AbbVie has received FDA approval for its new antibody-drug conjugate (ADC) drug, Emrelis. This approval marks a significant milestone for AbbVie, as Emrelis is designed to treat specific types of lung cancer. The drug's accelerated approval underscores its potential to improve patient outcomes and solidify AbbVie's position in the oncology market.